Cargando…

SuperDRUG2: a one stop resource for approved/marketed drugs

Regular monitoring of drug regulatory agency web sites and similar resources for information on new drug approvals and changes to legal status of marketed drugs is impractical. It requires navigation through several resources to find complete information about a drug as none of the publicly accessib...

Descripción completa

Detalles Bibliográficos
Autores principales: Siramshetty, Vishal B, Eckert, Oliver Andreas, Gohlke, Björn-Oliver, Goede, Andrean, Chen, Qiaofeng, Devarakonda, Prashanth, Preissner, Saskia, Preissner, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5753395/
https://www.ncbi.nlm.nih.gov/pubmed/29140469
http://dx.doi.org/10.1093/nar/gkx1088
_version_ 1783290267450736640
author Siramshetty, Vishal B
Eckert, Oliver Andreas
Gohlke, Björn-Oliver
Goede, Andrean
Chen, Qiaofeng
Devarakonda, Prashanth
Preissner, Saskia
Preissner, Robert
author_facet Siramshetty, Vishal B
Eckert, Oliver Andreas
Gohlke, Björn-Oliver
Goede, Andrean
Chen, Qiaofeng
Devarakonda, Prashanth
Preissner, Saskia
Preissner, Robert
author_sort Siramshetty, Vishal B
collection PubMed
description Regular monitoring of drug regulatory agency web sites and similar resources for information on new drug approvals and changes to legal status of marketed drugs is impractical. It requires navigation through several resources to find complete information about a drug as none of the publicly accessible drug databases provide all features essential to complement in silico drug discovery. Here, we propose SuperDRUG2 (http://cheminfo.charite.de/superdrug2) as a comprehensive knowledge-base of approved and marketed drugs. We provide the largest collection of drugs (containing 4587 active pharmaceutical ingredients) which include small molecules, biological products and other drugs. The database is intended to serve as a one-stop resource providing data on: chemical structures, regulatory details, indications, drug targets, side-effects, physicochemical properties, pharmacokinetics and drug–drug interactions. We provide a 3D-superposition feature that facilitates estimation of the fit of a drug in the active site of a target with a known ligand bound to it. Apart from multiple other search options, we introduced pharmacokinetics simulation as a unique feature that allows users to visualise the ‘plasma concentration versus time’ profile for a given dose of drug with few other adjustable parameters to simulate the kinetics in a healthy individual and poor or extensive metabolisers.
format Online
Article
Text
id pubmed-5753395
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-57533952018-01-05 SuperDRUG2: a one stop resource for approved/marketed drugs Siramshetty, Vishal B Eckert, Oliver Andreas Gohlke, Björn-Oliver Goede, Andrean Chen, Qiaofeng Devarakonda, Prashanth Preissner, Saskia Preissner, Robert Nucleic Acids Res Database Issue Regular monitoring of drug regulatory agency web sites and similar resources for information on new drug approvals and changes to legal status of marketed drugs is impractical. It requires navigation through several resources to find complete information about a drug as none of the publicly accessible drug databases provide all features essential to complement in silico drug discovery. Here, we propose SuperDRUG2 (http://cheminfo.charite.de/superdrug2) as a comprehensive knowledge-base of approved and marketed drugs. We provide the largest collection of drugs (containing 4587 active pharmaceutical ingredients) which include small molecules, biological products and other drugs. The database is intended to serve as a one-stop resource providing data on: chemical structures, regulatory details, indications, drug targets, side-effects, physicochemical properties, pharmacokinetics and drug–drug interactions. We provide a 3D-superposition feature that facilitates estimation of the fit of a drug in the active site of a target with a known ligand bound to it. Apart from multiple other search options, we introduced pharmacokinetics simulation as a unique feature that allows users to visualise the ‘plasma concentration versus time’ profile for a given dose of drug with few other adjustable parameters to simulate the kinetics in a healthy individual and poor or extensive metabolisers. Oxford University Press 2018-01-04 2017-11-11 /pmc/articles/PMC5753395/ /pubmed/29140469 http://dx.doi.org/10.1093/nar/gkx1088 Text en © The Author(s) 2017. Published by Oxford University Press on behalf of Nucleic Acids Research. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Database Issue
Siramshetty, Vishal B
Eckert, Oliver Andreas
Gohlke, Björn-Oliver
Goede, Andrean
Chen, Qiaofeng
Devarakonda, Prashanth
Preissner, Saskia
Preissner, Robert
SuperDRUG2: a one stop resource for approved/marketed drugs
title SuperDRUG2: a one stop resource for approved/marketed drugs
title_full SuperDRUG2: a one stop resource for approved/marketed drugs
title_fullStr SuperDRUG2: a one stop resource for approved/marketed drugs
title_full_unstemmed SuperDRUG2: a one stop resource for approved/marketed drugs
title_short SuperDRUG2: a one stop resource for approved/marketed drugs
title_sort superdrug2: a one stop resource for approved/marketed drugs
topic Database Issue
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5753395/
https://www.ncbi.nlm.nih.gov/pubmed/29140469
http://dx.doi.org/10.1093/nar/gkx1088
work_keys_str_mv AT siramshettyvishalb superdrug2aonestopresourceforapprovedmarketeddrugs
AT eckertoliverandreas superdrug2aonestopresourceforapprovedmarketeddrugs
AT gohlkebjornoliver superdrug2aonestopresourceforapprovedmarketeddrugs
AT goedeandrean superdrug2aonestopresourceforapprovedmarketeddrugs
AT chenqiaofeng superdrug2aonestopresourceforapprovedmarketeddrugs
AT devarakondaprashanth superdrug2aonestopresourceforapprovedmarketeddrugs
AT preissnersaskia superdrug2aonestopresourceforapprovedmarketeddrugs
AT preissnerrobert superdrug2aonestopresourceforapprovedmarketeddrugs